Form 4: Marinus Pharmaceuticals CFO Steven Pfanstiel Reports Stock and Option Awards

CFO and COO of Marinus Pharmaceuticals, Steven Pfanstiel, reports the acquisition of restricted stock units and stock options.

Summary

• Steven Pfanstiel, CFO and COO of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On June 18, 2024, Pfanstiel was granted 12,733 restricted stock units (RSUs) which vest on July 15, 2025, contingent upon continued service with Marinus Pharmaceuticals.
• Each RSU represents the right to receive one share of common stock.
• Pfanstiel also acquired a stock option to purchase 57,300 shares of common stock at an exercise price of $1.40, which vests fully on July 15, 2025, also contingent upon continued service.
• Following these transactions, Pfanstiel beneficially owns 84,430 shares of common stock and options for 57,300 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, incentivizing management. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to the CFO and COO aligns his interests with those of the shareholders.
• The vesting schedule tied to continued service incentivizes long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of executive compensation and are common in the pharmaceutical industry to incentivize key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the pharmaceutical industry, often used to attract and retain talent.
• Vesting schedules tied to continued service are also common, aligning executive interests with long-term company performance.
• Comparable companies like Sage Therapeutics or Biogen also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The equity grants align management's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, restricted stock units, Marinus Pharmaceuticals, MRNS, Steven Pfanstiel, CFO, COO